8-K - InMed Pharmaceuticals Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

InMed Pharmaceuticals Inc. provided a 2026 pharmaceutical development outlook, highlighting progress on INM-901 for Alzheimer's disease and INM-089 for dry age-related macular degeneration. The company plans a pre-IND meeting with the FDA for INM-901 in Q3 2026 and targets IND submission and Phase 1 trial initiation in 2027.

Key Takeaways

1Pre-IND meeting with FDA for INM-901 in Q3 2026

2IND submission and Phase 1 clinical trial initiation for INM-901 targeted for 2027

3Pre-IND meeting planned for INM-089 in Q4 2026

4INM-901 reduced inflammatory biomarkers IFN-γ, TNF-α, IL-1β, KC-GRO, IL-2, NfL in 5xFAD mouse model

5INM-901 demonstrated neuroprotection, neuritogenesis, and positive behavioral trends in preclinical studies

Current Report Details

Event Type

Regulation Fd

Exhibits Only

Disclosure

Voluntary

Variant

8-K

Items Reported

7.01

, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act,

Regulation Fd

9.01

. Financial Statements and Exhibits. (d) Exhibits: The following exhibits shall be deemed to be furnished, and not filed: Exhibit No. Description 99.1 News rele

Exhibits Only

Source Document

Exhibits (2)

8-K

FORM 8-K

99.1

EXHIBIT 99.1